Cancer Biology & Genetics Program

The Scott Lowe Lab

Research

Scott Lowe
Scott W. Lowe, PhD
Chair, Cancer Biology & Genetics Program, SKI; Chair, Geoffrey Beene Cancer Research Center; Investigator, Howard Hughes Medical Institute

About the Scott Lowe Lab

Cancer biologist Scott Lowe uses genetically engineered mouse models to study how the genetic alterations in cancer cells contribute to tumorigenesis, alter treatment response, and create molecular vulnerabilities that may be targeted therapeutically.

Cancer arises through an evolutionary process whereby normal cells acquire mutations that erode growth controls. Still, cancer is not an inevitable consequence of mutation, but is kept in check by intrinsic tumor-suppressor programs activated in damaged cells. We study such programs to reveal, and ultimately exploit, the strategies nature uses to combat cancer.

Our early studies focused on cell-intrinsic programs that prevent tumorigenesis (e.g., apoptosis, senescence), and have broadened to cell-extrinsic mechanisms (e.g., immune surveillance). New areas of interest include how tumor-suppressive programs are blunted by environmental factors known to increase cancer incidence (e.g., obesity, aging) and how excessive activation of tumor-suppressive programs (e.g., senescence) can harm function of normal tissue. To gain a mechanistic understanding of these phenomena, we apply mouse models in which cancer arises in an intact tissue ecosystem, which is a long-standing strength of our program. Our affiliation with Memorial Sloan Kettering Cancer Center enables us to probe human systems as well.

Another major goal is to harness our knowledge of tumor suppression therapeutically. We and others have shown that reengaging tumor-suppressive programs in established cancer cells can coordinate tumor regression through both cell-intrinsic and cell-extrinsic components (1-5), so these programs represent attractive strategies for tumor control. With Michel Sadelain, we have also developed a cell therapy approach to remove excessive senescent cells from tissues (6); this therapy may have beneficial effects on cancer and non-cancer pathologies. Advancing these concepts are major goals of our current research. 

Follow Lowe Lab on Twitter!

View Lab Overview

Research Projects

Publications Highlights

Chaves-Perez A, Millman SE, Janaki-Raman S, Ho YJ, Hinterleitner C, Barthet VJA, Morris JP 4th, Barriga FM, Reyes J, Kyaw A, Pasolli HA, Pe’er D, Thompson CB, Finley LWS, Cross JR, Lowe SW. Metabolic adaptations direct cell fate during tissue regeneration. Nature. 2025 Jul;643(8071):468-477. doi: 10.1038/s41586-025-09097-6. Epub 2025 Jun 11. Erratum in: Nature. 2025 Jul;643(8072):E15. doi: 10.1038/s41586-025-09294-3. PMID: 40500453; PMCID: PMC12240837.

Burdziak C, Alonso-Curbelo D, Walle T, Reyes J, Barriga FM, Haviv D, Xie Y, Zhao Z, Zhao CJ, Chen HA, Chaudhary O, Masilionis I, Choo ZN, Gao V, Luan W, Wuest A, Ho YJ, Wei Y, Quail DF, Koche R, Mazutis L, Chaligné R, Nawy T, Lowe SW, Pe’er D.Science. 2023 May 12;380(6645):eadd5327. doi: 10.1126/science.add5327. Epub 2023 May 12.PMID: 37167403 

View All Publications

People

Scott Lowe

Scott W. Lowe, PhD

Chair, Cancer Biology & Genetics Program, SKI; Chair, Geoffrey Beene Cancer Research Center; Investigator, Howard Hughes Medical Institute

  • PhD, Massachusetts Institute of Technology
lowes@mskcc.org
Email Address
646-888-3342
Office Phone
Download CV
PDF File

Members

Valentin Barthet
Postdoctoral Researcher
Lynn Boss, MS
Administrative Coordinator
Caroline Broderick
Graduate Student
Andrea Chaikovsky
Postdoctoral Researcher
Almudena Chaves Perez
Postdoctoral Researcher
Isabella Del Priore, BS
Graduate Student
Aveline Filliol
Lead Program Manager
Hailey V. Goldberg
Graduate Student
Clemens Hinterleitner
Postdoctoral Researcher
Yu-Jui (Ray) Ho, PhD
Computational Biologist
Wei Luan, MD
Senior Research Technician
Domhnall McHugh, PhD
Postdoctoral Researcher
Riccardo Mezzadra
Postdoctoral Researcher
Nalin Ratnayeke
Postdoctoral Researcher
José Reyes
Postdoctoral Researcher
Janelle Simon, BS
Mouse Colony Manager
Exequiel Sisso
Research Technician
Sha Tian, MS
Senior Research Technician
Zeda Zhang
Postdoctoral Researcher
Direna Alonso Curbelo, PhD
Junior Group Leader, Cancer Science, IRB Barcelona, Spain
Francisco Barriga, PhD
Group Leader - Cancer Genome Engineering Lab Vall D´Hebron Institute of Oncology (VHIO)
Iris Appelmann, MD
Physician, University Hospital RWTH Aachen, Germany
Corina Amor Vegas
CSHL Independent Fellow at Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Ana Banito, PhD
Group Leader, German Cancer Research Center (DKFZ), Heidelberg, Germany
Benedikt Bosbach, PhD
Principal Scientist, CTI, Pfizer Research, New York
Chi-Chao Chen, MD
Data Scientist, Agios Pharmaceuticals, Inc., Cambridge, MA
Hsuan-An Chen
Postdoctoral Fellow at Rockefeller University, New York, NY
Chong Chen, PhD
Professor, Sichuan University, Sichuan, China
Lukas Dow, PhD
Assistant Professor, Weill Cornell Medical College, New York, NY
Saya Ebbesen, PhD
Director, Medical & Scientific Strategy, BluPrint Oncology, London
Katerina Hatzi, PhD
Senior Scientist, Oncology Biomarker Development, Genentech, San Francisco, CA
Shauna Houlihan, PhD
Associate Director, Liver Research, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY
Grace  Xiang  Li, MS
Postdoctoral Fellow, Harvard University, Cambridge, MA
Chun-Hao Huang, PhD
Co-Founder & CEO, Algen Biotechnologies, San Francisco, CA
Edward Kastenhuber, PhD
Scientific Lead, Loxo Oncology at Lilly
Thomas Kitzing, PhD
Senior Research Scientist, Philipps University of Marburg, Institute of Pharmacology, Germany
Josef  Leibold, MD
Group Leader, University of Tübingen, Germany
Kiki Yu Liu, PhD
Professor, Sichuan University, Sichuan, China
Geulah Livshits, PhD
Senior Research Analyst, Biotechnology and Pharmaceuticals, Chardan Capital Markets LLC, New York, NY
Bryan Ngo
Group Leader, Altos Labs, San Francisco, CA
Stella Paffenholz, PhD
Analyst, Nexttech, Boston, MA
Francisco Sánchez-Rivera, PhD
Assistant Professor of Biology, Massachusetts Institute of Technology, Cambridge, MA
Evangelia Loizou, PhD
Senior Research Associate, Intelligencia, New York, NY
Amaia Lujambio, PhD
Associate Professor, Mount Sinai School of Medicine, New York, NY
Eusebio Manchado Robles, PhD
Senior Principal Scientist, Novartis, Basel, Switzerland
Allison Mayle, Postdoctoral Researcher
Assistant Director, DNALC, Cold Spring Harbor Laboratory, New York
Ozlem Mert, PhD
Senior Scientist, Pfizer, San Francisco, CA
Cornelius Miething, PhD
Group Leader and Medical Fellow, University Medical Center Freiburg, Germany
John P. Morris IV, PhD
Assistant Professor, Department of Pharmacology, University of North Carolina, Chapel Hill, NC
Kevin P. O'Rourke, MD, PhD
Investments, Roivant Sciences, New York, NY
Cory Rillahan, MD, PhD
Clinical Fellow, Pediatrics, Boston Children's Hospital, Boston, MA
Marcus Ruscetti, PhD
Assistant Professor, Molecular, Cell & Cancer Biology, University of Massachusetts Medical School, Worcester, MA
Anna Saborowski, MD
Physician, Hannover Medical School, Germany
Michael Saborowski, MD
Physician, Hannover Medical School, Germany
Charles J Sherr
Chair, Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN
Nilgun Tasdemir, PhD
Senior Scientist, Functional Genomics, Target Sciences, Pfizer, New York, NY
Darjus Tschaharganeh, MD
Group Leader, German Cancer Research Center (DKFZ), Heidelberg, Germany
Susann Weissmueller, PhD
Strategic Partnering Associate, Roche, Basel, Switzerland
Zhen Zhao, MD PhD
Pathology Resident, The Mount Sinai Hospital, New York, NY
Sarah Ackermann
Research Specialist, Weill Cornell Medicine, New York, NY
James H. Ahn, MS
Research Technician
Erica Anderson, BS
Research Technician
Mayerlin Chalarca
Research Technician
Ho-Chung Chen, MS
Research Technician
Jonathan Fisher, BS
Research Technician
Danielle Grace, BS
Research Technician
Fernanda Luna, BA
Research Technician
Jamie Plevy, BSE MS
Research Technician
Katarzyna Rybczyk
Research Technician
Aditya S. Shroff, BS
Research Technician
Meredith Taylor, BS
Research Technician
Anahi Tehuitzil
Research Technician
Vincent Tem
Research Technician
Alexandra Wuest
Research Technician
Leah  Zamechek, MS
Laboratory Manager
Xin Fang
Research Technician
Kaloyan Tsanov, PhD
Incoming Assistant Professor at University of Chicago

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

Scott Lowe Lab Plasmid and Animal Requests

Request plasmids through Addgene More »

For plasmids not listed on Addgene, please contact our Lab Manager, Anne Trumble-Koncelik, trumblea@mskcc.org.

For animal requests, please contact our Mouse Colony Manager, Janelle Simon, simonj@mskcc.org.

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Scott W. Lowe discloses the following relationships and financial interests:

  • Algen
    Intellectual Property Rights
  • Blueprint Medicines
    Equity; Professional Services and Activities
  • Faeth Therapeutics, Inc
    Equity; Professional Services and Activities (Uncompensated)
  • Fate Therapeutics
    Intellectual Property Rights; Professional Services and Activities
  • Mirimus
    Equity; Professional Services and Activities
  • Oric Pharmaceuticals
    Equity; Professional Services and Activities
  • PMV Pharma
    Equity; Professional Services and Activities
  • Selectin Therapeutics, Inc.
    Equity; Professional Services and Activities (Uncompensated)
  • Senescea Therapeutics
    Equity; Intellectual Property Rights; Professional Services and Activities (Uncompensated)

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures